Drugs / MyVax
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00071955 | Mar 2003 → Jan 2009 | lymphoma | Genitope Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00017290 | Nov 2000 → ? | lymphoma | Genitope Corporation | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MyVax | “We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus granulocyte...” PMID 24799467 ↗ May 20141“a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax personalised immunotherapy)” PMID 19125383 ↗ Jan 2009 |
| Known as | Id-KLH | “a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax personalised immunotherapy)” PMID 19125383 ↗ Jan 2009 |
| Modality | Vaccine | “a specific vaccine (MyVax)” PMID 24799467 ↗ May 2014 |
| Route | Subcutaneous | “autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously (SC)” NCT00071955 ↗ |